Recent Updates
Recently added Catalysts
QURE

uniQure to Present at the Oppenheimer 25th Healthcare Conference - NYC

Key Takeaway: AMSTERDAM, The Netherlands, Dec. 5, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, today announced that its management will present at the Oppenheimer 25th Healthcare Conference - NYC, to be held December 10-11, 2014, at The Crowne Plaza Hot

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+425%
120-day peak, hindsight
Typical move
5.1%
average across 6 past catalysts
Cash runway
~7 mo
Medium dilution risk
Lead asset
rAAV2/5-PBGD vector dosage 1
Phase 1 · Acute Intermittent Porphyria

Full Press Release Details

AMSTERDAM, The Netherlands, Dec. 5, 2014 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, today announced that its management will present at the Oppenheimer 25th Healthcare Conference - NYC, to be held December 10-11, 2014, at The Crowne Plaza Hotel in New York City, NY, USA.
Date: December 11, 2014
Time: 9:45 a.m. (EST)
Location: The Crowne Plaza Hotel, New York City, NY, USA
Speaking for uniQure: J rn Aldag, Chief Executive Officer
To access a simultaneous webcast of Mr. Aldag's presentation via the internet, log on to the "Events" section on the Media page of the uniQure website at http://www.uniqure.com/news/calendar-of-events/.
A replay of the webcast will be available from uniQure's website for 30 days following the conference. Mr. Aldag's presentation will be available for download in PDF format immediately following the conference presentation in the "Events" section of the Media page of uniQure's website at http://www.uniqure.com/news/calendar-of-events/.
uniQure is delivering on the promise of gene therapy through single treatments with potentially curative results. We have developed a modular platform to rapidly bring new disease-modifying therapies to patients with severe disorders. We are engaged in multiple partnerships and have obtained regulatory approval of our lead product, Glybera, in the European Union for a subset of patients with LPLD. www.uniQure.com
Last updated: Dec 5, 2014